Home > Rheumatology > ACR 2020 > What Is Hot in Lupus Nephritis? > Lupus nephritis: new therapies on the horizon in 2020

Lupus nephritis: new therapies on the horizon in 2020

Presented By
Prof. Joan T. Merrill, Oklahoma Medical Research Foundation, USA
ACR 2020
Lupus nephritis is a major risk factor for morbidity and mortality in systemic lupus erythematosus. Three novel agents might have the potential to improve therapy in the future. Both the European and US guidelines for the management of lupus nephritis (LN) are almost 9 years old [1,2]. They propose mycophenolate mofetil (MMF) or cyclophosphamide as first-line agents with the addition of glucocorticoids for optimal responses. Second-line agents include rituximab or calcineurin inhibitors. Naturally, these current guidelines are mainly based on clinical evidence and do not account for new perceptions of pathology and the latest studies. Therefore, Prof. Joan T. Merrill (Oklahoma Medical Research Foundation, USA) covered the new therapies in the drug pipeline in 2020 for LN [3]. The first candidate is the anti-CD20 monoclonal antibody obinutuzumab that was evaluated as add-on treatment to MMF versus placebo plus MMF in...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on